Axim Biotechnologies, Inc. (AXIM): R&D Expense
Not updated since 2023-12-31. No annual report in US GAAP has been filed since. Companies that switch to IFRS reporting, as many foreign filers do, or stop filing are not updated here.
$125.5K
Year ended 2023-12-31
-33.5%
3-year compound annual growth
-42.8%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2023-12-31 | $125.5K | -18.3% | 2024-04-16, From 2023-01-01 |
| 2022-12-31 | $153.7K | -46.0% | 2024-04-16, From 2022-01-01 |
| 2021-12-31 | $284.9K | -33.2% | 2024-04-16, From 2021-01-01 |
| 2020-12-31 | $426.7K | n/a | 2022-04-19, From 2020-01-01 |
| 2019-12-31 | $0 | -100.0% | 2021-04-26, From 2019-01-01 |
| 2018-12-31 | $2.06M | +52.0% | 2020-05-20, From 2018-01-01 |
| 2017-12-31 | $1.35M | +474.3% | 2019-04-08, From 2017-01-01 |
| 2016-12-31 | $235.6K | -58.8% | 2018-03-15, From 2016-01-01 |
| 2015-12-31 | $571.5K | n/a | 2017-09-14, From 2015-01-01 |
| 2014-12-31 | $0 | n/a | 2016-04-18, From 2014-01-01 |